Inter Pharma (SET:IP) - Aandelenkoers, Nieuws & Analyse

IP Overzicht aandelen

Inter Pharma Public Company Limited produceert, importeert en distribueert voedingssupplementen voor mens en dier in Thailand. Meer informatie

IP fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	0/6
Prestaties in het verleden	2/6
Financiële gezondheid	4/6
Dividenden	0/6

Risicoanalyse

Winstmarges (0.6%) zijn lager dan vorig jaar (5.1%)

Heeft geen betekenisvolle marktkapitalisatie ( THB2B )

Inter Pharma Public Company Limited Concurrenten

Rojukiss International

SET:KISS

฿2.8b

Thai Nippon Rubber Industry Public

SET:TNR

฿2.7b

Do Day Dream

SET:DDD

฿2.8b

Asian Phytoceuticals

SET:APCO

฿3.0b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Inter Pharma
Historische aandelenkoersen
Huidige aandelenkoers	฿3.60
52 Week Hoogtepunt	฿7.30
52 Week Laag	฿3.12
Bèta	0.63
11 maand verandering	-11.76%
3 maanden verandering	-10.00%
1 Jaar Verandering	-34.27%
33 jaar verandering	-70.60%
5 jaar verandering	7.76%
Verandering sinds IPO	-9.00%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	IP	TH Personal Products	TH Markt
7D	5.9%	1.7%	0.3%
1Y	-34.3%	-11.8%	3.2%

Rendement versus industrie: IP presteerde slechter dan de TH Personal Products -sector, die het afgelopen jaar een rendement van -11.8 % opleverde.

Rendement versus markt: IP presteerde slechter dan TH Market, dat het afgelopen jaar een rendement van 3.2 % opleverde.

Prijsvolatiliteit

Is IP's price volatile compared to industry and market?
IP volatility
IP Average Weekly Movement	6.2%
Personal Products Industry Average Movement	5.6%
Market Average Movement	4.6%
10% most volatile stocks in TH Market	10.1%
10% least volatile stocks in TH Market	2.4%

Stabiele aandelenkoers: IP heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 6% ) van IP is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2006	n/a	Trinnawat Thanitnithiphan	www.interpharma.co.th

Inter Pharma Public Company Limited produceert, importeert en distribueert voedingssupplementen voor mens en dier in Thailand. Het bedrijf is actief in drie segmenten: Human Healthcare, Animal Healthcare en Hospital. Het bedrijf biedt producten voor de mens, zoals medische benodigdheden, voedingstherapie, cosmetica, aanvullende voedingsmiddelen, probiotische en prebiotische producten, gezonde voedingsproducten, algemene voedingsproducten, medische apparatuur en geneesmiddelen, enz.; functionele voedingsmiddelen en dranken; en farmaceutische producten; Het biedt ook producten voor de gezondheidszorg voor huisdieren en vee, waaronder medische benodigdheden, voedingstherapie, vaccins, aanvullende voedingsmiddelen, probiotische en prebiotische producten, gezonde voedingsproducten voor dieren, premium diervoeding, algemene diervoeding, medische apparatuur met betrekking tot verzorgingsproducten voor huisdieren en vee, enz.

Inter Pharma Public Company Limited Samenvatting

Hoe verhouden de winst en inkomsten van Inter Pharma zich tot de beurswaarde?
IP fundamentele statistieken
Marktkapitalisatie	฿2.18b
Inkomsten(TTM)	฿10.52m
Inkomsten(TTM)	฿1.81b

207.2x

Koers/Winstverhouding

1.2x

P/S-verhouding

Is IP overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
IP resultatenrekening (TTM)
Inkomsten	฿1.81b
Kosten van inkomsten	฿1.14b
Brutowinst	฿665.05m
Overige uitgaven	฿654.53m
Inkomsten	฿10.52m

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	0.017
Brutomarge	36.81%
Nettowinstmarge	0.58%
Schuld/Eigen Vermogen Verhouding	14.2%

Hoe presteerde IP op de lange termijn?

Bekijk historische prestaties en vergelijking

Dividenden

0.6%

Huidig dividendrendement

123%

Uitbetalingsratio

IP Overzicht aandelen

Risicoanalyse

Inter Pharma Public Company Limited Concurrenten

SET:KISS

฿2.8b

SET:TNR

฿2.7b

SET:DDD

฿2.8b

SET:APCO

฿3.0b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

New minor risk - Share price stability

Second quarter 2024 earnings released: EPS: ฿0.006 (vs ฿0.019 in 2Q 2023)

Investor sentiment deteriorates as stock falls 26%

New minor risk - Share price stability

First quarter 2024 earnings released: EPS: ฿0.042 (vs ฿0.066 in 1Q 2023)

Investor sentiment deteriorates as stock falls 40%

Recent updates

New minor risk - Share price stability

Second quarter 2024 earnings released: EPS: ฿0.006 (vs ฿0.019 in 2Q 2023)

Investor sentiment deteriorates as stock falls 26%

New minor risk - Share price stability

First quarter 2024 earnings released: EPS: ฿0.042 (vs ฿0.066 in 1Q 2023)

Investor sentiment deteriorates as stock falls 40%

Inter Pharma Public Company Limited Approves Dividend for the Year 2023, Payable on May 24, 2024

Now 20% overvalued

Dividend reduced to ฿0.035

Full year 2023 earnings: EPS and revenues miss analyst expectations

Inter Pharma Public Company Limited Proposes Dividend for the Year 2023, Payable on May 24, 2024

Less than half of directors are independent

Third quarter 2023 earnings released: EPS: ฿0.037 (vs ฿0.09 in 3Q 2022)

New minor risk - Market cap size

Consensus EPS estimates fall by 32%

Second quarter 2023 earnings released: EPS: ฿0.03 (vs ฿0.10 in 2Q 2022)

New minor risk - Share price stability

Investor sentiment deteriorates as stock falls 16%

Price target decreased by 9.7% to ฿18.10

Investor sentiment deteriorates as stock falls 25%

Inter Pharma Public Company Limited Announces CFO Changes

Investor sentiment deteriorates as stock falls 22%

First quarter 2023 earnings released: EPS: ฿0.11 (vs ฿0.10 in 1Q 2022)

Upcoming dividend of ฿0.18 per share at 1.6% yield

Price target decreased by 13% to ฿18.65

Inter Pharma Public Company Limited Announces Resignation of Terdkiat Prommool as Director

Consensus forecasts updated

Less than half of directors are independent

Second quarter 2022 earnings released: EPS: ฿0.10 (vs ฿0.086 in 2Q 2021)

Inter Pharma Public Company Limited announced that it has received THB 1.04314 billion in funding from Innobic LL Holding Company Limited

Inter Pharma Public Company Limited Approves Election of Directors

Inter Pharma Public Company Limited Announces Chief Financial Officer Changes

Consensus forecasts updated

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Price target increased to ฿26.00

High number of new and inexperienced directors

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Inter Pharma Public Company Limited Proposes Omission of Dividend Payment for 2021

Consensus forecasts updated

Consensus forecasts updated

Third quarter 2021 earnings released: EPS ฿0.088 (vs ฿0.064 in 3Q 2020)

Investor sentiment deteriorated over the past week

Second quarter 2021 earnings released: EPS ฿0.086 (vs ฿0.059 in 2Q 2020)

First quarter 2021 earnings released: EPS ฿0.091 (vs ฿0.048 in 1Q 2020)

Inter Pharma Public Company Limited Approves Cash Dividends for 2020, Payable on May 18, 2020

Revenue and earnings miss expectations

Full year 2020 earnings released: EPS ฿0.26 (vs ฿0.28 in FY 2019)

Inter Pharma Public Company Limited, Annual General Meeting, Apr 26, 2021

Inter Pharma Public Company Limited (SET:IP) entered into an agreement to acquire Certain Assets of Teva Pharma (Thailand) Co., Ltd. from Teva Pharma (Thailand) Co., Ltd. for THB 160 million.

Investor sentiment improved over the past week

Inter Pharma Public Company Replaces Amornsakdi Ketcharoon with Kamtorn Sila-On as an Independent Director, Audit Committee, Chairman of the Nomination and Remuneration Committee and Corporate Governance and Sustainable Development Committee, Effective February 8, 2021

New 90-day high: ฿19.70

Independent Director has left the company

Inter Pharma Public Company Limited Notifies the Resignation of Mr. Amornsakdi Ketcharoon from Independent Director, Audit Committee, Chairman of the Nomination and Remuneration Committee and Corporate Governance and Sustainable Development Committee ,Effective from January 31, 2021

Investor sentiment improved over the past week

New 90-day high: ฿14.00

New 90-day high: ฿13.60

Third quarter 2020 earnings released: EPS ฿0.09

Interpharma Public Company Limited Announces Director Changes

New 90-day high - ฿13.40